FDA Grants Priority Review to BeOne’s New Drug for Aggressive Blood Cancer
The FDA has accepted and fast-tracked BeOne Medicines’ new drug sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, a rare and fast-growing blood cancer.
NOTRELOAD AI
Deere & Company's 2026 Outlook Misses Expectations Amid Farm Economy Struggles
Deere forecasts fiscal 2026 net income of $4-4.75B, below estimates. Q4 profit drops to $1.06B as tariffs and weak crop prices pressure the farm equipment maker.
UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
Petco Raises 2025 Earnings Outlook as Turnaround Gains Traction
Petco boosts full-year earnings forecast to $395-397M as Q3 results beat expectations. Stock jumps 9% on CEO Anderson's successful transformation strategy.
NetApp Beats Q2 Earnings on Strong AI Storage Demand Growth
NetApp stock jumps after beating Q2 profit and revenue estimates. Strong AI data storage demand and raised annual forecast drive investor optimism.
Autodesk Beats Expectations, Raises Outlook on Strong Cloud Demand
Autodesk reported strong Q3 results with revenue of $1.85B, beating estimates. The design software maker raised full-year guidance driven by cloud subscriptions and AI integration.